SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Vesugen | Cardiogen | Testagen (KEDG) |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Reproductive Endocrinology |
| Pharmacology | KED tripeptide / experimental cell signalling | Experimental short peptide / cardiac tissue-culture research | Synthetic KEDG tetrapeptide; preclinical DNA/histone and endocrine research, not testosterone |
| PrimeCore Class | Class CExperimental / limited evidence | Class CExperimental / limited evidence | Class CExperimental / limited evidence |
| Evidence Grade | Grade EPreclinical evidence | Grade EPreclinical evidence | Grade EPreclinical evidence |
| Evidence boundary | Vesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials. | Cardiogen has preclinical myocardial-explant and animal data. Proliferation and p53 changes do not establish improved human cardiac function or survival. Supplier sequence, formulation and authorisation are unverified. It is not a substitute for evidence-based cardiac care. | Testagen is the synthetic KEDG tetrapeptide (Lys-Glu-Asp-Gly), not the Testagen TDS testosterone product studied in NCT02733133. Verified evidence is preclinical: HeLa-cell and DNA/histone experiments and thyroid models in hypophysectomized birds. No human therapeutic trial of exact KEDG was verified in this review; testosterone, fertility, thyroid-treatment and anti-aging benefits and human safety remain unestablished. Exact product authorisation requires verification, and absence from named anti-doping examples is not sport clearance. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations | English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
| Insufficient data in the current dataset |
| Sources |
| ||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions